# Effect of LEO 80185 Gel on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis Vulgaris

> **NCT01229098** · PHASE2 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 102 (actual)

## Conditions studied

- Psoriasis Vulgaris

## Interventions

- **DRUG:** LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)

## Key facts

- **NCT ID:** NCT01229098
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2011-09
- **Final completion:** 2011-10
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01229098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01229098, "Effect of LEO 80185 Gel on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis Vulgaris". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01229098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*